Wall Street Zen downgraded shares of Avalyn Pharma (NASDAQ:AVLN – Free Report) from a hold rating to a sell rating in a research report report published on Sunday morning,Wall Street Zen reports.
AVLN has been the subject of a number of other reports. Morgan Stanley lifted their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a research report on Thursday, August 13th. They issued a “sell (d+)” rating for the company. Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $52.00 target price for the company. Guggenheim started coverage on Avalyn Pharma in a report on Monday, May 25th. They set a “buy” rating and a $80.00 price target on the stock. Finally, Evercore started coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $60.00.
Check Out Our Latest Stock Report on AVLN
Avalyn Pharma Price Performance
Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.05. As a group, analysts anticipate that Avalyn Pharma will post -3.81 earnings per share for the current year.
Institutional Trading of Avalyn Pharma
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVLN. Bank of New York Mellon Corp bought a new position in Avalyn Pharma in the second quarter worth approximately $1,321,000. State Street Corp purchased a new stake in shares of Avalyn Pharma in the 2nd quarter worth $10,501,000. Braidwell LP purchased a new stake in shares of Avalyn Pharma in the 2nd quarter worth $26,382,000. Finally, Montanova Capital LLC bought a new position in Avalyn Pharma in the 2nd quarter worth $82,402,000.
About Avalyn Pharma
Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.
Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.
Featured Stories
- Five stocks we like better than Avalyn Pharma
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
